Good news is more than a year away. If it happens at all.
I am accumulating while waiting
1. baxter /grifols taking out momenta after new sivig/sfc data
2) momenta already shifted focus from the enoxaparin quagmire, the followup patents
will be more ironclad
3) for more nonsensical favoritism filed against woodcock when m-glatiramer gets the nod
4) when amphastar-watson fubar srouce tainted batches of heparin (like baxter), to see their science (or lack thereof) in resolving the situation
Could be short covering. Short interest down 25% in the last month to a one year low.
People are not buying. A few funds are required to include MNTA in the portfolio, and with the market up 200 plus the funds are buying the basket.